Four-Week Neoadjuvant 5% Imiquimod Before Mohs Micrographic Surgery for Melanoma In Situ: A Prospective Pilot Study
Description
Figure legend: Supplementary Figure 1: Detailed methods section. Expanded description of the methods employed in this investigation. Supplementary Figure 2A-B: Photos of histopathology of representative complete responder. (2A) Original biopsy from the left medial buccal cheek showing MIS characterized by asymmetric lentiginous junctional melanocytic proliferation of single and nests of melanocytes on sun-damaged skin. (2B) Mohs layer with MART-1 stain after 4 weeks of imiquimod treatment. Black arrows show normal melanocyte spacing along dermal-epidermal junction. Supplementary Figure 3: Active tumor debulking using topical imiquimod. Lesion and surrounding skin reacting to a course of topical imiquimod. Supplementary Table 1: Combined table showing patient demographics and clinical tumor response to imiquimod. Displayed data includes age/sex; tumor location; prior history of skin cancer; family history, past medical history; original tumor area (cm2), post-neoadjuvant tumor area (cm2); and tumor percent change in area.
Files
Steps to reproduce
Expanded description of the methods employed in this investigation